Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
GLYC's Cash-to-Debt is ranked lower than
99.99% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. GLYC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GLYC' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.87
GLYC's Equity-to-Asset is ranked lower than
99.99% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. GLYC: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
GLYC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55  Med: 0.84 Max: 0.95
Current: 0.87
0.55
0.95
Interest Coverage No Debt
GLYC's Interest Coverage is ranked higher than
67% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GLYC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 9.64
Beneish M-Score: 195174.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -60079.63
GLYC's Operating Margin % is ranked lower than
99.99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. GLYC: -60079.63 )
Ranked among companies with meaningful Operating Margin % only.
GLYC' s Operating Margin % Range Over the Past 10 Years
Min: -60079.63  Med: -74.13 Max: 23.83
Current: -60079.63
-60079.63
23.83
Net Margin % -59933.33
GLYC's Net Margin % is ranked lower than
99.99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. GLYC: -59933.33 )
Ranked among companies with meaningful Net Margin % only.
GLYC' s Net Margin % Range Over the Past 10 Years
Min: -59933.33  Med: -74.01 Max: 23.96
Current: -59933.33
-59933.33
23.96
ROE % -75.41
GLYC's ROE % is ranked lower than
99.99% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. GLYC: -75.41 )
Ranked among companies with meaningful ROE % only.
GLYC' s ROE % Range Over the Past 10 Years
Min: -137.43  Med: -41.42 Max: 34.84
Current: -75.41
-137.43
34.84
ROA % -65.07
GLYC's ROA % is ranked lower than
99.99% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. GLYC: -65.07 )
Ranked among companies with meaningful ROA % only.
GLYC' s ROA % Range Over the Past 10 Years
Min: -89.49  Med: -24.15 Max: 15.45
Current: -65.07
-89.49
15.45
ROC (Joel Greenblatt) % -5911.63
GLYC's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. GLYC: -5911.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GLYC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5911.63  Med: -1944.15 Max: 1059.77
Current: -5911.63
-5911.63
1059.77
GuruFocus has detected 3 Warning Signs with GlycoMimetics Inc $GLYC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GLYC Guru Trades in Q1 2016

Jim Simons 69,200 sh (+13.59%)
» More
Q2 2016

GLYC Guru Trades in Q2 2016

Paul Tudor Jones 55,000 sh (New)
Jim Simons 114,600 sh (+65.61%)
» More
Q3 2016

GLYC Guru Trades in Q3 2016

Jim Simons 134,100 sh (+17.02%)
Paul Tudor Jones Sold Out
» More
Q4 2016

GLYC Guru Trades in Q4 2016

Jim Simons 117,900 sh (-12.08%)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ABUS, OTCPK:PAIOF, OTCPK:PHGUF, NAS:MRTX, NAS:ALBO, AMEX:PLX, NAS:NVIV, NAS:DVAX, NAS:EVGN, OTCPK:BCDA, OTCPK:DGJI, OTCPK:BNOEF, NAS:ARWR, NAS:RDHL, NAS:PPHM, NAS:GNCA, NAS:CBMG, NAS:MDWD, NAS:ATHX, OTCPK:EGRN » details
Traded in other countries:GKO.Germany,
GlycoMimetics Inc is a clinical stage biotechnology company. The Company is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Ratios

vs
industry
vs
history
Forward PE Ratio 5.41
GLYC's Forward PE Ratio is ranked higher than
95% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. GLYC: 5.41 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.45
GLYC's PB Ratio is ranked lower than
99.99% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. GLYC: 3.45 )
Ranked among companies with meaningful PB Ratio only.
GLYC' s PB Ratio Range Over the Past 10 Years
Min: 1.81  Med: 3.09 Max: 5.3
Current: 3.45
1.81
5.3
PS Ratio 2083.29
GLYC's PS Ratio is ranked lower than
99.99% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. GLYC: 2083.29 )
Ranked among companies with meaningful PS Ratio only.
GLYC' s PS Ratio Range Over the Past 10 Years
Min: 3.94  Med: 10.64 Max: 4485
Current: 2083.29
3.94
4485
EV-to-EBIT 0.08
GLYC's EV-to-EBIT is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. GLYC: 0.08 )
Ranked among companies with meaningful EV-to-EBIT only.
GLYC' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.1  Med: -6.9 Max: 0.09
Current: 0.08
-26.1
0.09
EV-to-EBITDA 0.08
GLYC's EV-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. GLYC: 0.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLYC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.9  Med: -7 Max: 0.09
Current: 0.08
-26.9
0.09
Current Ratio 8.59
GLYC's Current Ratio is ranked lower than
99.99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. GLYC: 8.59 )
Ranked among companies with meaningful Current Ratio only.
GLYC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.59 Max: 21.83
Current: 8.59
2.14
21.83
Quick Ratio 8.59
GLYC's Quick Ratio is ranked lower than
99.99% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. GLYC: 8.59 )
Ranked among companies with meaningful Quick Ratio only.
GLYC' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 8.59 Max: 21.83
Current: 8.59
2.14
21.83
Days Sales Outstanding 3.00
GLYC's Days Sales Outstanding is ranked lower than
99.99% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. GLYC: 3.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLYC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.53  Med: 0.62 Max: 3
Current: 3
0.53
3

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.70
GLYC's Price-to-Net-Cash is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. GLYC: 3.70 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GLYC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.29  Med: 3.49 Max: 5.59
Current: 3.7
2.29
5.59
Price-to-Net-Current-Asset-Value 3.57
GLYC's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. GLYC: 3.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GLYC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.25  Med: 2.8 Max: 5.54
Current: 3.57
2.25
5.54
Price-to-Tangible-Book 3.45
GLYC's Price-to-Tangible-Book is ranked lower than
99.99% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GLYC: 3.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GLYC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 2.74 Max: 5.49
Current: 3.45
2.19
5.49
Price-to-Median-PS-Value 208.33
GLYC's Price-to-Median-PS-Value is ranked lower than
99.99% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. GLYC: 208.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLYC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 0.92 Max: 363.5
Current: 208.33
0.54
363.5
Earnings Yield (Greenblatt) % 1139.87
GLYC's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. GLYC: 1139.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLYC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1178.16
Current: 1139.87
0
1178.16

More Statistics

Revenue (TTM) (Mil) $0.05
EPS (TTM) $ -1.62
Beta2.98
Short Percentage of Float10.18%
52-Week Range $4.28 - 9.25
Shares Outstanding (Mil)23.07

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 60 50 41
EPS ($) -1.54 1.18 0.62 0.09
EPS without NRI ($) -1.54 1.18 0.62 0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
GlycoMimetics reports 4Q loss Mar 01 2017
GlycoMimetics reports 4Q loss Mar 01 2017
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2017
GLYCOMIMETICS INC Files SEC form 10-K, Annual Report Mar 01 2017
GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results Mar 01 2017
GlycoMimetics to Present at Cowen 37th Annual Health Care Conference Feb 28 2017
Pharma company executives debate drug pricing increases Jan 12 2017
How Dawson Geophysical Company (DWSN) Stacks Up Against Its Peers Dec 16 2016
GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase... Dec 05 2016
GLYCOMIMETICS INC Financials Nov 11 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Nov 10 2016
GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting Nov 08 2016
GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Nov 04 2016
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2016
GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development Nov 04 2016
GLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report Nov 04 2016
Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of... Nov 03 2016
GLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)